Jubilant Therapeutics Reports Positive Phase 1 JBI-802 Data for ASH Presentation
Jubilant Pharmova Ltd · Press Release · 11 Nov 2026, 1:50 am
Jubilant Therapeutics Reports Positive Phase 1 JBI-802 Data for ASH Presentation Jubilant Pharmova subsidiary Jubilant Therapeutics announced an oral presentation of Phase 1/2 clinical data for lead asset JBI-802 at the 68th ASH Annual Meeting on 14th Dec'26. As of 30th Jun'26, 100% of patients (8/8) initiating the 15 mg dose achieved >50% platelet reduction or platelet normalization by Week 3, with a 15-day median response time. Normalization was maintained up to 46 weeks, with 7 of 11 leukocytosis patients achieving complete hematologic response and no dose-limiting toxicities observed across 5–15 mg cohorts.
Original exchange filing (PDF)
More announcements from Jubilant Pharmova Ltd
- Investor Meet Outcome · 16 Nov 2026
- Press Release · 14 Nov 2026
- Un-audited Financial Results for the Quarter and Half Year ended September 30, 2026 · 14 Nov 2026
- Outcome of Board Meeting · 14 Nov 2026
- Jubilant Pharmova Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 14 Nov 2026
- Allotment · 06 Nov 2026
- Allotment of NCD · 06 Nov 2026
- Earning Webinar · 16 Nov 2026
